Original Research
Accepted on 10 Feb 2025
Post-Marketing Safety Re-evaluation of Placental Peptide Injection in China: A Large-Scale Multicenter Real-World Study
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1541005
Volumes
401 Publications
Review
Accepted on 10 Feb 2025
Targeting miRNA with Flavonoids: Unlocking Novel Pathways in Cardiovascular Disease Management
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1532986
Review
Accepted on 10 Feb 2025
Effects of Chinese Medicine on Modulating Interleukin-17regulated Macrophages in Coronary Heart Disease
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1499786
Perspective
Accepted on 10 Feb 2025
What role for real-world evidence in market access of biosimilars?
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1538866
Systematic Review
Accepted on 10 Feb 2025
Factors Influencing the Cost-effectiveness of Novel Oral Anticoagulants Compared to Vitamin K Antagonists in Patients with Atrial Fibrillation: A Systematic Review
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1441754
Technology and Code
Accepted on 10 Feb 2025
Integrating WHO's Digital Adaptation Kit for Antenatal Care into BornFyne-PNMS: Insights from Cameroon
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1474999
Original Research
Accepted on 10 Feb 2025
Marked differences in the effects of levetiracetam and its analogue brivaracetam on microglial, astrocytic-and neuronal density in the rat model of kainic acid-induced temporal lobe epilepsy
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1553545
Original Research
Accepted on 10 Feb 2025
Identification of Glycolysis-Related Gene Signatures for Prognosis and Therapeutic Targeting in Idiopathic Pulmonary Fibrosis
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1486357
Editorial
Accepted on 10 Feb 2025
Editorial: Pharmacological Advances to Treat Pathological Pain
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1571059
Original Research
Accepted on 10 Feb 2025
Exogenous Galectin-9 Prevents Peri-implantitis in Rats by Regulating Macrophage Polarization
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1533468
Original Research
Accepted on 10 Feb 2025
The association between the gut microbiome and antituberculosis drug-induced liver injury
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1512815
Original Research
Accepted on 10 Feb 2025
Novel Selective Glucocorticoid Receptor Modulator GRM-01 Demonstrates Dissociation of Anti-inflammatory Effects from Adverse Effects on Glucose and Bone Metabolism
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1542351
Original Research
Accepted on 10 Feb 2025
A combinatorial screening protocol for identifying novel and highly potent dual-target inhibitor of BRD4 and STAT3 for kidney cancer therapy
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1560559
Original Research
Accepted on 10 Feb 2025
Model-informed drug development of novel ROCK2 inhibitor TDI01: population pharmacokinetic study and simulation
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1477607
Original Research
Accepted on 10 Feb 2025
Signal mining and analysis of ripretinib adverse events: a real-world pharmacovigilance analysis based on the FAERS database
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1481114
Review
Accepted on 10 Feb 2025
Unleashing the Power of Peptides in Prostate Cancer Immunotherapy: Mechanism, facts and perspectives peptides for targeted therapy and immunological regulation against prostate cancer: Mechanism, facts and perspectives
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1478331